Clinical Universidad de Navarra and the Barcelona Institute for Global Health (ISGlobal), a center supported by "la Caixa” Foundation, have launched a clinical trial to investigate the efficacy of ivermectin against COVID-19. The study team will combine ivermectin with Idilfarma to determine whether administration of ivermectin is associated with a shorter clearance time.
Ivermectin was recently evidenced to inhibit the replication of SARS-CoV-2 in vitro at very high doses (Monash University, Australia), but this effect is now being tested in a number of studies from Johns Hopkins University to University of Kentucky in the United States, Tanta University in Egypt, as well as centers in Argentina and Iraq.
Titled the SARS-CoV-2 Ivermectin Navarra ISGlobal Trial (SAINT), the Spanish study’s investigators will probe with a randomized trial with 24 participants with mild cases of COVID-19 and no risk factors receiving a single oral dose of ivermectin or placebo less than 48 hours after the onset of the symptoms.
In the study, the newly diagnosed patients don’t require hospitalization, so follow-up is carried out in their homes during their period...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).